Khalid El Bairi: Considerations for the CHH–Lancet Commission on Health, Conflict, and Forced Displacement
Khalid El Bairi shared an article on LinkedIn:
“Happy to share our second paper in The Lancet, addressing an issue that healthcare systems face globally.
We hope our ideas will help in developing specific actions.”
Tittle: Considerations for the CHH–Lancet Commission on Health, Conflict, and Forced Displacement
Author: Khalid El Bairi and Dario Trapani
Source: Khalid El Bairi/LinkedIn
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies. El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023